Intra-cellular therapies reports q2 loss per share $0.96

Intra-cellular therapies reports second quarter 2020 financial results and provides corporate update.q2 loss per share $0.96.q2 earnings per share estimate $-0.91 -- refinitiv ibes data.qtrly total revenue $1.9 million.q2 revenue view $2.9 million -- refinitiv ibes data.

ITCI Ratings Summary

ITCI Quant Ranking